Super-Enhancer–FOXA1–SLC7A11 Axis Drives Disulfidptosis in Prostate Cancer

Study Background and Research Question

Prostate cancer (PCa) ranks among the most prevalent malignancies in men worldwide, with particularly high incidence and mortality rates in Western countries and a rising burden in Asian populations (Kang et al., 2025). While early-stage PCa often responds to androgen deprivation therapy, advanced cases frequently progress to castration-resistant prostate cancer (CRPC), characterized by persistent androgen receptor signaling and poor response to immune checkpoint inhibitors. As standard apoptosis and cell cycle arrest assays reveal, the complexity of tumor cell death modalities adds further challenges to therapeutic development. Recently, a novel programmed cell death mechanism, disulfidptosis, has been described. Unlike ferroptosis or apoptosis, disulfidptosis is triggered by cytoskeletal collapse under glucose deprivation in cells overexpressing SLC7A11—a cystine transporter (Kang et al., 2025). The current study sought to dissect the regulatory mechanisms controlling SLC7A11 and their role in PCa progression and therapy resistance.

Key Innovation from the Reference Study

Kang et al. provide the first detailed mechanistic map linking super-enhancer (SE) activity, the transcription factor FOXA1, and SLC7A11 expression to the induction of disulfidptosis in prostate cancer. Their central innovation is the identification of a super-enhancer at chr14:37583488–37589585 that orchestrates the SE/FOXA1/SLC7A11 axis, thereby modulating both tumor growth and susceptibility to this unique cell death pathway (Kang et al., 2025). This finding not only elucidates a novel regulatory cascade but also connects epigenetic control via super-enhancers to metabolic vulnerabilities in cancer cells, opening avenues to exploit disulfidptosis as a therapeutic strategy in aggressive, treatment-resistant PCa.

Methods and Experimental Design Insights

The investigators employed a multifaceted approach:

• Bioinformatics: Integration of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, alongside machine learning, identified disulfidptosis-related genes, focusing on SLC7A11.
• Functional Assays: Both SLC7A11-overexpressing and knockout PCa cell lines were generated to assess effects on proliferation, migration, invasion, and response to glucose deprivation.
• Induction of Disulfidptosis: Pharmacological inhibition of glucose uptake with BAY-876 was used to mimic metabolic stress and trigger disulfidptosis in vitro.
• Epigenomic Profiling: CUT&Tag and ChIP-seq identified FOXA1 as a direct transcriptional regulator of SLC7A11, driven by a defined super-enhancer region.
• Genetic Editing: CRISPR-Cas9 deletion of the super-enhancer region confirmed its necessity for maintaining FOXA1 and SLC7A11 expression and susceptibility to disulfidptosis.

This integrated experimental design allowed the authors to trace the pathway from epigenetic regulation to metabolic cell death and tumor phenotype.

Core Findings and Why They Matter

Key discoveries include:

• SLC7A11 Functions: Overexpression of SLC7A11 promotes proliferation, migration, and invasion in PCa cells, while also rendering them susceptible to disulfidptosis under glucose-starved conditions (Kang et al., 2025).
• FOXA1/SLC7A11 Regulation: The super-enhancer at chr14:37583488–37589585 recruits FOXA1, which in turn transcriptionally activates SLC7A11. This regulatory loop is crucial for both oncogenic behavior and cell death induction.
• Super-Enhancer Deletion: CRISPR-mediated removal of the super-enhancer reduces both FOXA1 and SLC7A11 expression, protecting cells from disulfidptosis and attenuating aggressive tumor characteristics.
• Therapeutic Implications: These results suggest that targeting the SE/FOXA1/SLC7A11 axis—especially under metabolic stress—may provide a new route for therapy in CRPC, where standard apoptosis-based interventions often fail.

This work highlights the translational potential of epigenetic modulators and defines a rationale for integrating super-enhancer targeting strategies in cancer biology.

Comparison with Existing Internal Articles

Recent reviews and workflows on I-BET151 (GSK1210151A), a selective BET bromodomain inhibitor, emphasize the broader utility of epigenetic targeting in cancer research (PrecisionFDA, 2023; Atrial-Natriuretic-Factor, 2023). These resources detail how BET inhibitors modulate oncogenic transcription programs by disrupting chromatin interactions—paralleling the super-enhancer mechanisms described in the current PCa study. For example, I-BET151 has demonstrated robust induction of G1 cell cycle arrest and apoptosis in MLL-fusion leukemia and glioblastoma assays, providing a practical reference for similar experimental frameworks (PrecisionFDA, 2023). The methodologies for chromatin modulation and apoptosis assay integration align well with the disulfidptosis-focused protocols in the Kang et al. study, underscoring the convergence of epigenetic and metabolic targeting strategies in advanced cancer models.

Protocol Parameters

• apoptosis assay | 24–48 h post-treatment | PCa and leukemia models | Standard window for detecting programmed cell death following epigenetic or metabolic interventions | paper, workflow_recommendation
• cell cycle arrest assay | 5–10 µM I-BET151 for 24 h | MLL-fusion leukemia, glioblastoma, PCa | Validated range for G1 arrest induction using BET inhibition | product_spec, workflow_recommendation
• CRISPR-Cas9 enhancer deletion | sgRNA targeting chr14:37583488–37589585 | PCa cell lines | Mechanistic validation of enhancer function | paper
• glucose deprivation/disulfidptosis induction | 0.5–1 mM glucose, ±BAY-876 | SLC7A11-overexpressing PCa cells | Mimics tumor metabolic stress to trigger disulfidptosis | paper

Limitations and Transferability

The study's major strength—integrating multi-omic profiling with functional genomics—also sets certain limitations. Most experiments were confined to in vitro and cell-based models, and while the regulatory axis is compelling, further in vivo validation in primary and metastatic PCa is necessary. Additionally, the focus on a single super-enhancer limits generalizability to other regulatory regions or tumor types. Transferability to other cancers will require careful mapping of enhancer–transcription factor–target gene networks and consideration of unique metabolic dependencies. Nonetheless, the methodology—especially the combination of chromatin editing, apoptosis assay, and cell cycle arrest workflow—can inform research design in broader cancer biology contexts (Atrial-Natriuretic-Factor, 2023).

Research Support Resources

For researchers aiming to explore epigenetic modulation of super-enhancer–driven transcription programs or to integrate apoptosis and cell cycle arrest assays, validated reagents are essential. I-BET151 (GSK1210151A) (SKU B1500) from APExBIO is widely referenced as a selective BET bromodomain inhibitor for cancer biology workflows (source: product_spec). Its use enables precise interrogation of transcriptional dependencies in advanced cancer models, supporting the types of mechanistic and functional studies exemplified by Kang et al. Researchers are advised to follow recommended storage and solubility protocols for optimal results (source: product_spec).